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Melanotransferrin (MTf) or melanoma tumor antigen p97 is a membrane-bound transferrin (Tf) homologue that binds iron (Fe). This
protein is also found as a soluble form in the plasma (sMTf) and was suggested to be an Alzheimer’s disease marker. In addition, sMTf has
been recently suggested to cross the blood–brain barrier (BBB) and accumulate in the brain of the mouse following intravenous infusion.
Considering the importance of this observation to the physiology and pathophysiology of the BBB and the function of sMTf in vivo, we
investigated the uptake and distribution of 59Fe-125I-sMTf and compared it to 59Fe-125I-Tf that were injected intravenously in rats. Studies
were also performed to measure 59Fe and 125I-protein uptake by reticulocytes using these radiolabelled proteins. The results showed that
sMTf was rapidly catabolized, mainly in the liver and to a lesser extent by the kidneys. The 59Fe was largely retained by these organs but
the 125I was released into the plasma. Only a small amount of 125I-sMTf or its bound 59Fe was taken up by the brain, less than that from
59Fe-125I-Tf. There was much less 59Fe uptake by erythropoietic organs (spleen and femurs) from 59Fe-sMTf than from 59Fe-Tf, and no
evidence of receptor-mediated uptake of sMTf was obtained using reticulocytes. It is concluded that compared to Tf, sMTf plays little or no
role in Fe supply to the brain and erythropoietic tissue. However, a small amount of sMTf was taken up from the plasma by the brain and a
far greater amount by the liver.
D 2004 Elsevier B.V. All rights reserved.Keywords: Transferrin; Melanotransferrin; Iron transport; Iron metabolism
1. Introduction The human MTf molecule has many properties in com-Melanotransferrin (MTf) is a homologue of the serum
Fe-binding protein, transferrin (Tf) (for reviews, see Refs.
[1,2]). Interestingly, MTf was initially identified as the
oncofetal antigen p97 that was found at high levels in fetal
tissues but also in tumors, particularly malignant melanoma
[3–5]. However, in later reports, MTf was identified not
only in neoplastic cells but also in a variety of normal
tissues [6–9].0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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homology with human serum Tf, human lactoferrin, and
chicken Tf; (ii) the MTf gene is on chromosome 3, as are
those for Tf and the Tf receptor 1 (TfR1); (iii) many of the
disulfide bonds present in serum Tf and lactoferrin are also
present in MTf; (iv) MTf has an N-terminal Fe-binding site
that is similar to that found in serum Tf; and (v) isolated and
purified MTf can bind one Fe atom/molecule from Fe(III)
citrate [3,10–13]. This circumstantial evidence suggested
that MTf played a role in Fe transport (for review, see Ref.
[2]). A major difference between serum Tf and MTf was
that the latter was bound to the cell membrane by a glycosyl
phosphatidylinositol (GPI) anchor [6,14].
The only well-characterized function of MTf is its ability
to bind Fe [11]. However, studies examining the possible
role of MTf in melanoma cells where it is expressed at very
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efficient cellular Fe uptake mechanism in comparison to the
high-affinity TfR1 [8,15–17]. Furthermore, MTf expres-
sion, unlike that of the TfR1, is not regulated by intracellular
Fe levels, and it is not expressed at high levels in tissues
with high Fe requirements (e.g., placenta, liver or bone
marrow) [8]. While transfection of cells with very high non-
physiological levels of MTf leads to increased Fe uptake
from Fe-citrate [18], this Fe uptake route does not appear
significant in melanoma cells [8]. These studies suggest that
MTf plays a different role to the TfR1 that is involved in Fe
uptake from the serum Fe-binding protein, Tf [2,8]. Various
functions for membrane-bound MTf have been suggested
[8], and recently it has been proposed to play roles in
chondrogenesis, angiogenesis, cell migration and the regu-
lation of plasminogen activation [19,20]. However, defini-
tive proof of its physiological or pathophysiological role in
normal and neoplastic cells has not been forthcoming.
Apart from MTf that is bound to the cell membrane by a
GPI anchor [6,14], a soluble form of MTf (sMTf) exists in
the serum of patients with melanoma [21] and Alzheimer’s
disease [22,23]. Splice variants of MTf have also been
identified in humans, and one of these may encode a soluble
molecule that correlates to that found in the serum [24]. In
fact, it was suggested that sMTf could act as a marker for
Alzheimer’s disease, as the concentration of this molecule
in the serum was reported to be elevated in these patients
[22]. However, more recent investigations have challenged
this view, demonstrating technical problems in this latter
study [25].
Previous investigations using surface labelling of SK-
Mel-28 melanoma cells demonstrated that partitioning of
membrane MTf from the cell surface into the extracellular
milieu was unlikely, and that active secretion of a high Mr
(95–97 kDa) form of sMTf occurred [14]. Hypothetically,
in vivo, sMTf could bind Fe released from the liver, and
then donate it back to the cell via a putative sMTf receptor
or to the TfR1. However, recent studies by Food et al. [26]
have shown that recombinant human sMTf is not bound by
the TfR1 nor any other high-affinity receptors by human
melanoma cells and other cell types in culture. Indeed, sMTf
donates Fe to cells far less effectively than Tf via a low
affinity process consistent with surface pinocytosis [26].
Experiments by others using recombinant human sMTf
from the same source as that utilized in our laboratory [26]
demonstrated that this molecule became highly accumulated
in mouse brain following intravenous injection and in situ
brain perfusion [27–29]. Furthermore, the transcytosis of
human sMTf across bovine brain capillary endothelial cell
monolayers was at least 14-fold higher than holo-Tf and
there was no intra-endothelial degradation of the molecule
[27,28]. The trans-endothelial transport of sMTf appeared to
be via receptor-mediated endocytosis and the authors sug-
gested this was mediated by the low-density lipoprotein-
related protein (LRP) [27,28]. However, these latter reports
did not examine the distribution of sMTf in the serum orother tissues and this may be critical in terms of under-
standing the metabolism of the molecule. Furthermore, it
was unclear whether holo-sMTf or the apo-form of the
molecule was used in the latter investigations [27,28].
Clearly, the presence of Fe bound to the high-affinity
binding site of sMTf could markedly influence its biological
activity in a similar way to that found for the serum Fe-
binding molecule, Tf [30]. The aims of this investigation
were to rectify the omissions from the earlier studies and to
provide essential information on the possible role of sMTf
as an Fe transport molecule in vivo in comparison to the
well characterized function of Tf in the rat [31,32]. Indeed,
this is essential considering that the biological role of MTf
remains unknown.2. Materials and methods
2.1. Protein preparation, purification and labelling
Human apo-transferrin (apo-Tf) was from Sigma Chem-
ical Co. (St. Louis, MO, USA) and human apo-sMTf was
kindly provided by Dr. Malcolm Kennard, Synapse Tech-
nologies Inc, Vancouver, Canada. The sMTf was genetically
engineered to be deficient of the final 27 amino acids at the
C-terminal, thus abolishing the GPI-attachment signal [33].
Purity of sMTf was confirmed by SDS-PAGE [33] which
yielded one band at 95 kDa. Considering this, the protein
sequence of sMTf (710 amino acids) predicts a Mr of 78
kDa. This suggests post-translational modification consis-
tent with glycosylation. Comparison of endoglycosidase-H
resistance between sMTf from SK-Mel-28 cells [14] and
that secreted from the BHK TK cell line [33], suggested
both proteins were glycosylated in a similar way. Mass
spectroscopy studies and N-terminal sequence analysis
(Australian Proteome Analysis Facility, Macquarie Univer-
sity, Sydney, NSW) performed on sMTf derived from BHK
TK cells demonstrated that it was the correct size and
sequence. Previous studies have shown that this form of
sMTf reacted with a panel of anti-MTf monoclonal anti-
bodies (L235, HybC, 2C7, 9B6) in the same way as sMTf
released from SK-Mel-28 melanoma cells [33]. These
results indicated that the tertiary structure of these molecules
were very similar, and the fact that sMTf bound Fe (see
below) suggested that this protein was correctly folded.
Apo-Tf and apo-sMTf were labelled with 59Fe (Dupont
NEN, MA, USA) or 56Fe to produce holo-diferric transferrin
(59Fe-Tf) or holo-monoferric sMTf (59Fe-sMTf) using estab-
lished procedures [15,34]. Briefly, the apo-proteins were
saturated with Fe using the ferric nitrilotriacetate complex
using a molar ratio of 1 Fe:10 NTA. The complex was
prepared using FeCl3 in 0.1 M HCl and then the solution
was adjusted to pH 7.4 using 1.4% NaHCO3 [15,34]. The Fe
concentration in this solution was calculated to just ensure
saturation of the Fe-binding site(s) without causing undue
non-specific adsorption to the protein. Both sMTf and Tf
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and two [1,30] high-affinity Fe-binding sites per molecule,
respectively. For both proteins, upon Fe-loading, the
expected colour change from clear to salmon pink was
observed. The UV–Vis absorption maximum of monoferric
sMTf was 464 nm, as described in previous studies [10].
The apo-proteins were added to the Fe-containing solution
and incubated for 1 h at room temperature prior to dialysis.
Free 59Fe or 56Fe bound to NTAwas removed by exhaustive
dialysis against a large excess of 0.15 M NaCl buffered to
pH 7.4 with 1.4% NaHCO3 [15,34].
To examine the uptake of the proteins and Fe by tissues
and cells, 59Fe-labelled monoferric sMTf and diferric Tf
were labelled with 125I by the gentle iodine monochloride
method [35] followed by extensive dialysis as described
above. In these studies, the amount of free 125I in the protein
sample was measured via trichloroacetic acid precipitation
(see below) and was always less than 1.0% of the total 125I
in the protein samples. Our previous studies showed that Tf
and sMTf labelled with 59Fe and 125I using the current
methods resulted in functional proteins [1,15,26,34,36,37].
In all experiments examining the uptake of the 125I-sMTf or
125I-Tf, the proteins were also saturated with 59Fe via the
procedures above. These dual labelling experiments enabled
examination of the uptake of both the 59Fe label and the
125I-labelled protein using well-established procedures in
our laboratories [15,26,31,32,34,38].
Rat albumin was purified and labelled with 131I by the
iodine monochloride method, as described previously [31].
2.2. Animal welfare
All procedures dealing with the handling of animals in
this study were approved by the Animal Ethics Committee
of the University of Western Australia.
2.3. Plasma disappearance and tissue uptake of 59Fe-125I-Tf
and 59Fe-125I-sMTF by the rat
Male rats of the Wistar strain weighing 197–269 g were
used. These animals were injected intravenously by the
lateral tail vein with 50 Al of 59Fe-125I-Tf (150 Ag protein)
or 59Fe-125I-sMTf (100 Ag protein) under halothane anes-
thesia. Blood was collected into microhematocrit tubes 2
min after injection and at various times thereafter from the
ventral tail vein under halothane anesthesia. At the end of
the experiment, the animal was sacrificed using an intraper-
itoneal injection of sodium pentobarbitone and blood was
removed from the right ventricle of the heart using a
heparinized syringe. Rats were then perfused with 60 ml
of heparinized 0.15 M NaCl via the left ventricle, organs
removed and kept on ice. The liver, brain and two kidneys
were then homogenized with ice-cold 0.15 M NaCl and
proteins precipitated using 10% trichloroacetic acid [39].
The resultant supernatant and precipitate were placed in
plastic g-counting tubes and radioactivity measured using ag-scintillation counter (LKB Wallac 1282 Compugamma,
LKB, Uppsala, Sweden). Other organs, spleen and femurs,
were placed whole into g-counting tubes and radioactivity
then determined.
Three to five minutes prior to the sacrifice of the rat, the
animal was injected via the lateral tail vein with 50 Al of
131I-labelled rat albumin (200 Ag). The 131I-albumin values
within the plasma and tissues were used to determine the
plasma volume of the animals and to correct the 59Fe and
125I values of the tissues for their residual content of plasma
(called ‘‘plasma-free’’ values in the Results section).
It should be noted that since human sMTf was used in
our studies, human Tf was implemented to enable a relevant
comparison in terms of assessing the uptake of 59Fe and the
125I-labelled proteins by rat tissues. It is well known that
human Tf interacts with rat TfRs and donates Fe by a
receptor-mediated process to rat cells [40].
2.4. Immunoprecipitation of rat Tf from plasma
Immunoprecipitation of rat Tf was used to determine
whether the 59Fe in the plasma of rats injected with
59Fe-125I-sMTf remained on the sMTf or was transferred
to the circulating rat Tf. Blood from rats injected with 50
Al of 59Fe-125I-sMTf was taken from the heart at 15, 30, 60,
120 and 240 min after the initial injection. Plasma was then
separated by centrifugation (1500 g/10 min at 4 jC) and a
rabbit anti-rat Tf polyclonal antibody [41] was added,
followed by incubation at 37 jC for 30 min and at 4 jC
for 60 min to immunoprecipitate rat Tf. Optimization
experiments were performed to determine the quantity of
anti-rat antibody required to achieve complete precipitation
of all rat Tf by this procedure.
2.5. Uptake of labelled sMTf and Tf by reticulocytes
The uptake of radioactively labelled proteins by reticu-
locytes was performed using standard techniques [38]. The
cells, containing 50–60% reticulocytes, were washed three
times with ice-cold 0.15 M NaCl and then suspended in
Hanks’ balanced salt solution (BSS; Gibco). Radiolabelled
sMTf or Tf were added and the cells incubated at 37 jC for
varying times in an oscillating water bath. Following this,
they were washed three times with ice-cold 0.15 M NaCl,
incubated for 30 min at 4 jC with the general protease,
Pronase (1 mg/ml; Boehringer Mannheim, Mannheim, Ger-
many), and then centrifuged at 1000 g for 10 min at 4 jC.
This procedure separates membrane-bound 59Fe and 125I
which is released into the incubation solution and intracel-
lular 59Fe and 125I that are retained by the cells [15–
17,34,38,42,43]. Radioactivity in the supernatant and cells
was then counted using the g-counter described above.
Three types of experiments were performed. (1) The cells
were incubated with 0.5 AM 59Fe-125I-sMTf or 59Fe-125I-Tf
for varying times up to 20 min at 37 jC. (2) The cells were
incubated for 15 min at 37 jC with varying concentrations
Table 1
T1/2 values for the two slopes obtained when the plasma disappearance
curves of 59Fe-125I-Tf and 59Fe-125I-sMTf in the rat (Fig. 1) were analyzed
as two exponentials
T1/2 (min) Proportion (%)
Fast Slow Fast Slow
125I-Tf 54 1997 56 44
59Fe-Tf 23 136 88 12
125I-sMTf 7 53 76 24
59Fe-sMTf 8 62 69 31
Also shown is the proportion of each disappearance curve associated with
the fast and slow slopes expressed as percentages.
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cells were incubated in BSS at 37 jC for 15 min with
Pronase (1 mg/ml), washed three times with ice-cold 0.15 M
NaCl and then incubated at 37 jC for 15 min with 0.5 AM
59Fe-125I-sMTf or 59Fe-125I-Tf.
2.6. Statistics
All of the in vivo experiments were performed with
four rats per group. Results are expressed as the mean-
sF S.E., except for the plasma disappearance curves where
each point represents the value obtained in one animal.
Significance of the differences between the means of the
four animal groups (P < 0.05) was assessed using Student’s
t-test.3. Results
3.1. Plasma clearance and tissue uptake of 59Fe-125I-sMTf
and 59Fe-125I-Tf
Initial experiments compared the ability of human
59Fe-125I-Tf and human 59Fe-125I-MTf to be taken up by
the rat model that was previously well characterized in our
laboratory in terms of assessing 59Fe-125I-Tf uptake [30–
32]. These experiments were essential considering first, theFig. 1. The clearance of 59Fe-125I-sMTf and 59Fe-125I-Tf from the plasma of
rats after intravenous injection. Rats were injected in the lateral tail vein
with 59Fe-125I-sMTf or 59Fe-125I-Tf. Then, after various times, blood was
collected from the ventral tail vein and also from the heart at the end of the
study (see Materials and methods for details). The results are from a total of
40 animals, i.e., 20 animals injected with 59Fe-125I-sMTf and 20 injected
with 59Fe-125I-Tf. The clearance curves were obtained by analyzing the data
for two exponentials and this was performed using the Prism program from
Graphpad Software (California, USA).previous studies suggesting that human sMTf can actively
cross the mouse blood–brain barrier (BBB) to the brain
[27–29], and second, that the physiological function of MTf
remains elusive.
After intravenous injection of 59Fe-125I-sMTf into rats,
protein-bound 125I disappeared from the plasma far more
quickly than after 59Fe-125I-Tf injection (Fig. 1). TheFig. 2. The plasma-free uptake of 59Fe from 59Fe-125I-sMTf (–o–) and
59Fe-125I-Tf (–.– ) into the liver, kidney, spleen and brain of the rat
calculated as a percentage of the injected dose. Rats were injected in the
lateral tail vein with 59Fe-125I-sMTf and 59Fe-125I-Tf and the uptake of 59Fe
into tissues determined with correction for the plasma content of the tissue.
The liver, brain and two kidneys were homogenized and proteins
precipitated using 10% trichloroacetic acid. The spleens were placed whole
into counting tubes and radioactivity then determined (see Materials and
methods for details). The results are meansF S.E. from four rats for each
experimental part.
Fig. 3. The uptake of 125I from 59Fe-125I-sMTf (–o– ) and 59Fe-125I-Tf
(–.–) into the liver, kidney, spleen and brain of the rat calculated as a
percentage of the injected dose. Rats were injected in the lateral tail vein with
59Fe-125I-sMTf and 59Fe-125I-Tf and the uptake of 125I into tissues
determined with correction for the plasma content of the tissue as described
in Materials and methods. The liver, brain and two kidneys were
homogenized and proteins precipitated with trichloroacetic acid. The results
for these organs show the protein-bound 125I. The spleen was counted
whole, and hence, the spleen results represent total plasma-free 125I. These
data are from the same animals as in Fig. 2.
Fig. 4. The uptake of 125I from 59Fe-125I-sMTf (–o– ) and 59Fe-125I-Tf
(–.– ) into liver, kidneys, spleen and brain expressed as plasma/tissue ratio
of radioactivity at the time the tissues were sampled, as described in the
text. The results are from the same animals as in Fig. 2.
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than that from 59Fe-125I-sMTf. In the case of 59Fe-125I-Tf,
the clearance of 59Fe was much faster than that of 125I-Tf.
By contrast, with 59Fe-125I-sMTf, clearances of 125I-sMTf
and 59Fe were similar (Fig. 1). After 240 min, the proportion
of protein-free 125I in the plasma, as determined by tri-
chloroacetic acid precipitation, was less than 1% of the total
125I in all animals injected with 59Fe-125I-Tf. This result
indicated a high proportion of intact 125I-labelled Tf in the
serum. However, protein-free 125I was much higher after
59Fe-125I-sMTf injection, rising from a mean of approxi-
mately 9% at 15 min, to 20% at 60 min, and 30% at 120 and
240 min, suggesting degradation of 125I-labelled sMTf.
The plasma clearance results were assessed by least-
squares analysis and found to fit well to double exponential
curves, as shown in Fig. 1. The half-time values for these
exponentials are given in Table 1, along with the proportion
of each clearance curve associated with the fast and slow
components. These results emphasize the more rapid clear-
ance of protein-bound 125I, and to a lesser extent, 59Fe
derived from 59Fe-125I-sMTf than from 59Fe-125I-Tf withrespect to both the fast and slow components of the
disappearance curves. In these studies, 56–88% of the
isotopes were removed from the plasma by the early, rapid
clearance process.
Two patterns of 59Fe uptake by the organs were observed
(Fig. 2). In the liver and kidney, uptake from 59Fe-125I-sMTf
was greater than from 59Fe-125I-Tf. Approximately 60% of
the 59Fe derived from 59Fe-125I-sMTf was taken up by the
liver and 6% by the kidneys (Fig. 2). The other pattern was
observed in the spleen and brain. In these organs, 59Fe
uptake from 59Fe-125I-Tf was more pronounced than from
59Fe-125I-sMTf (Fig. 2). The pattern of 59Fe uptake by the
two femurs was similar to that in the spleen, where uptake
from 59Fe-125I-Tf was greater than from 59Fe-125I-sMTf
(data not shown). However, the total uptake of 125I-Tf by
the femurs was lower than the spleen, being approximately
3% of the dose (data not shown).
When expressed as a percentage of the injected dose, the
protein-bound 125I values were greater in liver and kidney
and lower in brain (Fig. 3) after injection of 59Fe-125I-sMTf
in comparison to 59Fe-125I-Tf. In the case of the liver and
kidneys, maximum values of approximately 30% and 6% of
the dose, respectively, were observed at the first time point
after injection (i.e., at 15 min). The results for 125I uptake by
the spleen are also shown in Fig. 3, but it should be noted
that trichloroacetic acid precipitation was not performed
Fig. 5. Immunoprecipitation of rat plasma Tf after injection of the rat with
human 59Fe-125I-sMTf. Samples of plasma from rats injected with human
59Fe-125I-sMTf were precipitated using anti-rat Tf as described in Materials
and methods and the radioactivity measured in the immunoprecipitates. The
results are expressed as the percentage of plasma 59Fe and protein-bound
125I, which was precipitated by the antibody.
 
Fig. 6. Internalization of 59Fe-125I-transferrin (Tf) and 59Fe-125I-melano-
transferrin (sMTf) by rabbit reticulocytes in vitro. Rabbit reticulocytes were
incubated for 15 min at 37 jC with a range of 59Fe-125I-Tf and 59Fe-125I-
sMTf concentrations (0.05–1.5 AM). Internalization of 59Fe and the 125I-
labelled proteins was then assessed by incubation with Pronase (1 mg/ml)
for 30 min at 4 jC (see Materials and methods for details). Results are
means of duplicate determinations in a typical experiment from two
separate experiments performed.
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was higher after 59Fe-125I-sMTf injection at the early time
points than after 59Fe-125I-Tf injection, but lower 120 and
240 min after injection.
A second way of expressing the 125I uptake by the organs
is as tissue/plasma concentration ratios, calculated by divid-
ing the 125I radioactivity as cpm/g tissue by the cpm/ml
plasma. This estimation was performed so as to allow
comparison with the results observed in the mouse by
Demeule et al. [28] that used this method to express their
data. As shown in Fig. 4, this calculation resulted in higher
values in all of the organs examined (including femurs, data
not shown) after injection of 59Fe-125I-sMTf rather than
after 59Fe-125I-Tf.
3.2. Immunoprecipitation of rat Tf from plasma
Considering that 59Fe-125I-sMTf was rapidly cleared
from the plasma (Fig. 1) and the 59Fe taken up in mainly
the liver and kidney (Fig. 2), experiments were designed to
assess if 59Fe that was originally bound to 59Fe-125I-sMTf
could then be reutilized. Indeed, it is well known that a
proportion of 59Fe taken up by the liver can be released
back into the circulation to bind to Tf [30]. In these
studies, plasma from rats injected with 59Fe-125I-sMTf
(100 Ag) was taken at 15, 30, 60, 120 and 240 min afterthe initial injection. Rabbit anti-rat polyclonal antibody
was then added to immunoprecipitate rat Tf and assess
the levels of 59Fe bound by this latter protein (Fig. 5). A
large proportion of the plasma 59Fe was precipitated by the
antiserum, rising rapidly from about 25% at 15 min to
more than 50% at 30 min and to greater than 90% at 240
min (Fig. 5). Only about 10% of the 125I was precipitated
with the antiserum, showing that very little of the 59Fe
precipitated could be due to precipitation of 59Fe-125I-sMTf
by the antiserum (Fig. 5).4. The uptake of 59Fe-125I-Tf or 59Fe-125I-sMTf by
reticulocytes in vitro
Experiments were then designed to compare the ability of
59Fe-125I-Tf or 59Fe-125I-sMTf to be internalized by and
donate 59Fe to reticulocytes (Fig. 6). This experimental
model was chosen for these studies as the uptake of
59Fe-125I-Tf by these cells via receptor-mediated endocyto-
sis of the TfR1 has been extensively characterized [30,38].
The intracellular uptake of 59Fe by reticulocytes from
59Fe-125I-Tf was linear with time for at least 20 min and
was approximately 15 times greater than that from
59Fe-125I-sMTf (results not shown). The uptake of 59Fe
and 125I-protein as a function of ligand concentration
showed evidence of saturation as the 59Fe-125I-Tf concen-
tration increased above 0.5 AM (Fig. 6), as shown in
previous studies [30,38]. However, 59Fe-125I-sMTf uptake
was linear in relation to concentration and much lower
than with 59Fe-125I-Tf (Fig. 6). This result indicated the
receptor-mediated nature of Tf but not sMTf uptake. A
similar conclusion was obtained using reticulocytes from
which receptors had been removed by prior treatment with
the general protease, Pronase [15,34,38,42]. The uptake of
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the control value by this treatment, but there was no
reduction in 125I-sMTf or sMTf-59Fe uptake (results not
shown).5. Discussion
The aim of the present study was to assess the role of the
Tf homologue, MTf, in donating Fe to tissues in comparison
to serum Tf. Both MTf and Tf contain 1 and 2 high-affinity
Fe-binding sites, respectively [1,10,30], and while the role of
Tf in Fe transport is well described [1,30], little is known
about the biological function of MTf. Indeed, a number of
hypotheses regarding the possible functions of MTf have
been suggested [2]. Recent studies have reported that human
sMTf can cross the BBB and accumulate in the mouse brain
following intravenous infusion [27–29]. Potentially, this is
an important observation in elucidating the physiology of the
BBB and the biological function of sMTf in the brain and
other organs and its possible role in Alzheimer’s disease.
After injection of radiolabelled Tf into the rat, the
clearance of 59Fe from the plasma was more rapid than
that of 125I-Tf. This is undoubtedly due to receptor-medi-
ated uptake of the Tf mainly by erythropoietic tissues (in
these experiments exemplified by the spleen and femurs)
and liver, as has been shown conclusively for this molecule
[30]. This is followed by recycling of the protein to the
circulation without catabolism [30]. However, in clear
contrast to Tf, sMTf and its bound Fe were rapidly cleared
from the circulation, mainly by the liver and to a lesser
extent by the kidneys and other organs. The 125I-sMTf was
catabolized in these organs with release of 125I back to the
plasma in a form which was mainly non-precipitable by
trichloroacetic acid. The 59Fe derived from sMTf was
largely retained by the liver and kidneys. However, some
was recycled to the plasma where it can be bound by the
circulating rat Tf and thereby becomes available to tissues
which possess TfRs. In particular, Fe uptake was marked in
tissues which express high levels of the TfR1 such as
erythropoietic tissue and liver [30]. This conclusion was
supported by results obtained after immunoprecipitation of
rat Tf from the plasma. The biphasic nature of the plasma
disappearance curves for 125I and 59Fe derived from sMTf
probably reflect these processes. That is, the initial rapid
clearance may be due to uptake and catabolism of the
labelled protein by the liver and kidneys, and the later,
slower clearance being the result of recycling of some of the
125I-sMTf and 59Fe. The quick removal of sMTf from the
circulation commenced immediately after its injection.
Hence, it cannot be due to an immunological reaction
against the human protein since this would take many
hours, even some days, to become detectable. More likely,
the fast clearance was due to a mechanism which was
already present in the tissues. Possibly this is due to the
presence of a receptor which is expressed to greatest extentin the liver but also at lower levels in the other organs
examined. The two phases in the fall in plasma 125I-Tf are
probably attributable to extravasation across the capillary
walls throughout the body (early phase) followed by return
to the circulation via the lymph and some catabolism (late
phase) mainly in liver and kidneys, as demonstrated previ-
ously for this protein [32].
The sMTf donated extremely little 59Fe to the brain in the
rat. In fact, this was only 10% of that provided by Tf (Fig.
2). When expressed as a percentage of dose administered,
the uptake of protein-bound 125I by the brain was less with
sMTf than with Tf (Fig. 3). This appeared to contradict the
results obtained by Demeule et al. [28] who reported greater
brain uptake of sMTf than Tf in the mouse using the same
source of recombinant sMTf. However, these latter authors
presented their results in terms of the brain/serum concen-
tration ratio 1 h after injection of the proteins [28]. When
this method was implemented in the present study, a greater
apparent uptake of sMTf than Tf was observed (Fig. 4). This
was due to the very rapid clearance of the sMTf and much
slower clearance to Tf from the circulation, so that by the
time the measurements were made, the calculated ratio
provides a false impression of the relative uptake of sMTf
compared with Tf by the brain in these in vivo experiments.
However, this does not exclude the possibility that some
sMTf is able to pass from plasma into brain, as suggested by
the results of in vitro investigations with cultured bovine
brain capillary cell monolayers and an in situ brain perfu-
sion study [28].
Overall, considering the studies of Demeule et al. [28]
and Moroo et al. [29] in the mouse, one may conclude that
sMTf can be transferred across the BBB from plasma to the
brain. However, the current investigation in the rat sug-
gested that the fraction of the total circulating pool of sMTf
involved in this process is very small. Hence, the use of
sMTf to mediate the transfer of pharmacologically active
substances into the brain [28,44,45] would probably be an
inefficient process if the same occurs in humans. In addition,
it is unlikely that plasma sMTf contributes significantly to
the amount of Fe which is transported into the brain of the
rat, the major transport mechanism being mediated by Tf.
Indeed, our current data are in direct contrast to the report of
Moroo et al. [29] in which Fe-labelled sMTf was reported to
be far more effective than Fe-labelled Tf at delivering Fe to
the brain. These latter authors have then speculated that
sMTf is an important Fe transport mechanism in the brain
under physiological conditions and also in neurodegenera-
tive diseases such as Alzheimer’s disease [29]. However,
relative to Tf that is present in the serum at 2–3 mg/ml [30],
the levels of sMTf in the serum are extremely low (7 ng/ml
in normal patients compared to 44 ng/ml in Alzheimer’s
disease; [22]). Moreover, there is controversy on whether
sMTf is raised in the serum of Alzheimer’s disease patients
[25]. In fact, technical difficulties have been cited [25] as the
reason for the enhanced levels of sMTf reported in this latter
condition [22].
D.R. Richardson, E.H. Morgan / Biochimica et Biophysica Acta 1690 (2004) 124–133 131In the current study, we used techniques to label Tf and
sMTf with 59Fe and 125I that are well-established in our
laboratories and have been previously shown to maintain
the functional characteristics of these molecules [15–
17,26,31,32,34,36–38,40,43]. For instance, the iodine
monochloride method is well known to maintain protein
integrity as it does not use harsh oxidants such as
chloramine T [35]. If this method had denatured Tf or
sMTf, the proteins would not have retained their charac-
teristic ‘‘salmon pink’’ colour that is dependent upon the
secondary structure of the protein(s) to maintain their
active Fe-binding site(s). Moreover, nor would Tf donate
Fe to reticulocytes and show saturable binding to the TfR1
on these and other cell types (see Fig. 6 and Refs.
[15,26,34,38]). In addition, the functional integrity of these
proteins after labelling was ensured by competition studies
where the labelled or non-labelled protein acted in the
same manner to block the uptake of 59Fe-125I-Tf or
59Fe-125I-sMTf [26]. Another important fact is that both
sMTf and Tf were labelled by the same 59Fe and 125I-
labelling procedures, whereas the uptake of both these
proteins was very different in the rat (see Figs. 2 and 3). If
they had been denatured by the iodination procedure, they
would probably have been taken up in the same way by
reticuloendothelial organs. Collectively, the methods and
controls implemented ensure that sMTf and Tf were not
denatured by the labelling procedures used.
It should be noted that because human sMTf was used in
our studies, human Tf was implemented to enable a relevant
comparison in terms of assessing the uptake of 59Fe and the
125I-labelled proteins by rat tissues and rabbit reticulocytes.
Although such heterologous systems may not be ideal, they
are acceptable alternatives to performing the experiments in
humans for several reasons. First, human Tf interacts with
rat and rabbit TfRs and efficiently donates Fe by receptor-
mediated processes to rat cells in vitro [40,46]. Second, the
plasma clearance curves and tissue uptake results for 59Fe
and 125I-Tf observed in the present study after intravenous
injection of radiolabelled human Tf are very similar to those
previously observed using rat Tf [47,48]. Third, when direct
comparisons were made in vivo in the rat, the uptake of Fe
by liver, femurs and brain from rat, human and rabbit Tfs
were found to be almost identical [49,50].
The results for 59Fe uptake by the spleen and femurs in
vivo and by reticulocytes in vitro show that sMTf provides
very little Fe for developing erythroid cells and that the
small amount of Fe taken up by these cells from sMTf does
not occur by a receptor-mediated process. The latter con-
clusion is based on the observations of much lower and non-
saturable uptake of Fe from sMTf than from Tf by retic-
ulocytes and the failure to reduce Fe uptake from sMTf by
pre-treatment of cells with the proteinase, Pronase, whereas
uptake from Tf was nearly completely inhibited by this
treatment. Certainly, one can conclude that Fe uptake by
immature erythroid cells from sMTf does not involve the
TfR1 which is released from the cell by Pronase treatment[15,38,42]. Probably other membrane receptors would also
be released by this treatment. Hence, it is likely that the Fe
uptake by the cells from sMTf occurs by non-specific
processes, as was concluded earlier in several other cell
types in culture [26].
The conclusion reached above does not rule out the
possibility that sMTf uptake by the brain, liver, kidneys,
spleen and femurs does involve receptor-mediated process-
es. Indeed, Beliveau [27,28] have suggested that uptake of
sMTf by the mouse brain involves the low-density LRP or
related receptors of the low density lipoprotein receptor
family. These receptors are highly expressed in the liver and
to lower levels in most other organs and on brain capillaries
[51,52]. This could possibly explain the relative levels of
uptake of sMTf by the organs which was observed in the
present investigation.Acknowledgements
Children’s Cancer Institute Australia for Medical Re-
search is affiliated with the University of New South Wales
and Sydney Children’s Hospital. This project was supported
by a fellowship and projects grant from the National Health
and Medical Research Council of Australia and a Large
Grant from the Australian Research Council (ARC). The
authors kindly thank Synapse Ltd. and Biomarin Ltd. for
their very kind gifts of sMTf and in particular the help of Dr.
Malcolm Kennard and Dr. R. Gabathuler.References
[1] D.R. Richardson, P. Ponka, The molecular mechanisms of the metab-
olism and transport of iron in normal and neoplastic cells, Biochim.
Biophys. Acta 1331 (1997) 1–40.
[2] E. Sekyere, D.R. Richardson, The membrane-bound transferrin ho-
mologue melanotransferrin: roles other than iron transport? FEBS
Lett. 483 (2000) 11–16.
[3] J.P. Brown, K. Nishiyama, I. Hellstro¨m, K.E. Hellstro¨m, Structural
characterization of human melanoma-associated antigen p97 with
monoclonal antibodies, J. Immunol. 127 (1981) 539–546.
[4] R.G. Woodbury, J.P. Brown, S.M. Loop, K.E. Hellstro¨m, I. Hellstro¨m,
Analysis of normal and neoplastic human tissues for the tumor-asso-
ciated protein p97, Int. J. Cancer 27 (1981) 145–149.
[5] R.G. Woodbury, J.P. Brown, M.Y. Yeh, I. Hellstro¨m, K.E. Hellstro¨m,
Identification of a cell surface protein, p97, in human melanoma and
certain other neoplasms, Proc. Natl. Acad. Sci. U. S. A. 77 (1980)
2183–2187.
[6] R. Alemany, M. Rosa Vila´, C. Franci, G. Egea, F.X. Real, J.M.
Thompson, Glycosyl phosphatidylinositol membrane anchoring of
melanotransferrin (p97): apical compartmentalization in intestinal ep-
ithelial cells, J. Cell. Sci. 104 (1993) 1155–1162.
[7] W.A. Jefferies, M.R. Food, R. Gabathuler, S. Rothenberger, T.
Yamada, O. Yasuhara, P.L. McGeer, Reactive microglia specifically
associated with amyloid plaques in Alzheimer’s disease brain tissue
express melanotransferrin, Brain Res. 712 (1996) 122–126.
[8] D.R. Richardson, The role of melanotransferrin (tumor antigen p97)
in iron uptake by the human malignant melanoma cell, Eur. J. Bio-
chem. 267 (2000) 1290–1298.
D.R. Richardson, E.H. Morgan / Biochimica et Biophysica Acta 1690 (2004) 124–133132[9] R. Sciot, R. De Vos, P. van Eyken, K. van der Steen, P. Moerman, V.J.
Desmet, In situ localization of melanotransferrin (melanoma-associ-
ated antigen P97) in human liver. A light- and electron-microscopic
immunohistochemical study, Liver 9 (1989) 110–119.
[10] E.N. Baker, H.M. Baker, C.A. Smith, M.R. Stebbins, M. Kahn, K.E.
Hellstro¨m, I. Hellstro¨m, Human melanotransferrin (p97) has only one
functional iron-binding site, FEBS Lett. 298 (1992) 215–218.
[11] J.P. Brown, R.H. Hewick, I. Hellstro¨m, K.E. Hellstro¨m, R.F. Doolittle,
W.J. Dreyer, Human melanoma antigen p97 is structurally and func-
tionally related to transferrin, Nature 296 (1982) 171–173.
[12] G.D. Plowman, J.P. Brown, C.A. Enns, J. Schro¨der, B. Nikinmaa,
H.H. Sussman, K.E. Hellstro¨m, I. Hellstro¨m, Assignment of the gene
for human melanoma-associated antigen p97 to chromosome 3, Na-
ture 303 (1983) 70–72.
[13] T.M. Rose, G.D. Plowman, D.B. Teplow, W.J. Dreyer, K.E. Hell-
stro¨m, J.P. Brown, Primary structure of human melanoma-associat-
ed antigen p97 (melanotransferrin) deduced from the mRNA
sequence, Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 1261–1265.
[14] M.R. Food, S. Rothenberger, R. Gabathuler, I.D. Haidl, G. Reid, W.A.
Jefferies, Transport and expression in human melanomas of a trans-
ferrin-like glycosylphosphatidylinositol-anchored protein, J. Biol.
Chem. 269 (1994) 3034–3040.
[15] D.R. Richardson, E. Baker, The uptake of iron and transferrin by the
human melanoma cell, Biochim. Biophys. Acta 1053 (1990) 1–12.
[16] D.R. Richardson, E. Baker, The release of iron and transferrin by
the human melanoma cell, Biochim. Biophys. Acta 1091 (1991)
294–304.
[17] D. Richardson, E. Baker, The uptake of inorganic iron complexes by
human melanoma cells, Biochim. Biophys. Acta 1093 (1991) 20–28.
[18] M.L. Kennard, D.R. Richardson, R. Gabathuler, P. Ponka, W.A. Jeff-
eries, A novel iron uptake mechanism mediated by GPI-anchored
human p97, EMBO J. 14 (1995) 4178–4186.
[19] M. Demeule, Y. Bertrand, J. Michaud-Levesque, J. Jodoin, Y. Roll-
and, R. Gabathuler, R. Beliveau, Regulation of plasminogen activa-
tion: a role for melanotransferrin (p97) in cell migration, Blood 102
(2003) 1723–1731.
[20] R. Sala, W.A. Jefferies, B. Walker, J. Yang, J. Tiong, S.K. Law, M.F.
Di Marco, E. Di Marco, A. Vacca, R. Cancedda, F.D. Cancedda, D.
Ribatti, The human melanoma associated protein melanotransferrin
promotes endothelial cell migration and angiogenesis in vivo, Eur.
J. Cell Biol. 81 (2002) 599–607.
[21] J.P. Brown, R.G. Woodbury, C.E. Hart, I. Hellstro¨m, K.E. Hellstro¨m,
Quantitative analysis of melanoma-associated antigen p97 in normal
and neoplastic tissues, Proc. Natl. Acad. Sci. U. S. A. 78 (1981)
539–543.
[22] M.L. Kennard, H. Feldman, T. Yamada, W.A. Jefferies, Serum levels
of the iron binding protein p97 are elevated in Alzheimer’s disease,
Nat. Med. 2 (1996) 1230–1235.
[23] D.K. Kim, M.Y. Seo, S.W. Lim, S. Kim, J.W. Kim, B.J. Carroll, D.Y.
Kwon, T. Kwon, S.S. Kang, Serum melanotransferrin, p97 as a bio-
chemical marker of Alzheimer’s disease, Neuropsychopharmacology
25 (2001) 84–90.
[24] E. Sekyere, M.R. Food, D.R. Richardson, A second melanotransferrin
gene (MTf2) and a novel protein isoform: explanation for the mem-
brane-bound and soluble forms of melanotransferrin? FEBS Lett. 512
(2002) 350–352.
[25] R.R. Desrosiers, Y. Bertrand, Q.T. Nguyen, M. Demeule, R. Gabath-
uler, M.L. Kennard, S. Gauthier, R. Beliveau, Expression of melano-
transferrin isoforms in human serum: relevance to Alzheimer’s
disease, Biochem. J. 374 (2003) 463–471.
[26] M. Food, E.O. Sekyere, D.R. Richardson, The soluble form of the
membrane-bound transferrin homologue, melanotransferrin, ineffi-
ciently donates iron to cells via non-specific internalisation and deg-
radation of the protein, Eur. J. Biochem. 269 (2002) 4435–4445.
[27] R. Beliveau, Vectorization of proteins across the blood–brain barrier:
high transcytosis of melanotransferrin, J. Neurochem. 85 (Suppl. 2)
(2003) 7.[28] M. Demeule, J. Poirier, J. Jodoin, Y. Bertrand, R.R. Desrosiers, C.
Dagenais, T. Nguyen, J. Lanthier, R. Gabathuler, M. Kennard, W.A.
Jefferies, D. Karkan, S. Tsai, L. Fenart, R. Cecchelli, R. Beliveau,
High transcytosis of melanotransferrin (p97) across the blood–brain
barrier, J. Neurochem. 83 (2002) 924–933.
[29] I. Moroo, M. Ujiie, B.L. Walker, J.W.C. Tiong, T.Z. Vitalis, D. Karkan,
R. Gabathuler, A.R. Moise, W.A. Jefferies, Identification of a novel
route of iron transcytosis across the blood–brain barrier, Microcircu-
lation 10 (2003) 457–462.
[30] E.H. Morgan, Transferrin biochemistry, physiology and clinical sig-
nificance, Mol. Aspects Med. 4 (1981) 1–123.
[31] M.E. Gardiner, E.H. Morgan, Transferrin and iron uptake by the liver
in the rat, Aust. J. Exp. Biol. Med. Sci. 52 (1974) 723–736.
[32] M.E. Strahan, A. Crowe, E.H. Morgan, Iron uptake and transferrin
degradation in the brain and other tissues of the rat, Am. J. Physiol.
263 (1992) R924–R929.
[33] J. Yang, Deletion of the GPI pre-anchor sequence in MTf as a mech-
anism for generating the soluble form of the protein, MSc Thesis,
Department of Zoology, University of British Columbia, Vancouver,
Canada, 1999.
[34] D.R. Richardson, E. Baker, Two mechanisms of iron uptake from
transferrin by melanoma cells. The effect of desferrioxamine and
ferric ammonium citrate, J. Biol. Chem. 267 (1992) 13972–13979.
[35] A.S. McFarlane, Efficient trace labelling of protein with iodine, Na-
ture 182 (1958) 53.
[36] S. Paterson, N.J. Armstrong, B.J. Iacopetta, H.J. McArdle, E.H. Mor-
gan, Intravesicular pH and iron uptake by immature erythroid cells, J.
Cell. Physiol. 120 (1984) 225–232.
[37] D. Trinder, E.H. Morgan, E. Baker, The mechanisms of iron uptake
by rat fetal hepatocytes, Hepatology 6 (1986) 852–858.
[38] B.J. Iacopetta, E.H. Morgan, The kinetics of transferrin endocytosis
and iron uptake from transferrin in rabbit reticulocytes, J. Biol. Chem.
258 (1983) 9108–9115.
[39] T. Skogh, Overestimate of 125I-protein uptake from the adult mouse
gut, Gut 23 (1982) 1077–1080.
[40] F.M. van Bockxmeer, E.H. Morgan, Comparative aspects of transfer-
rin– reticulocyte interactions: membrane receptors and iron uptake,
Comp. Biochem. Physiol. 71A (1982) 211–218.
[41] E.H. Morgan, Factors affecting the synthesis of transferrin in rat tissue
slices, J. Biol. Chem. 244 (1969) 4193–4199.
[42] M. Karin, B. Mintz, Receptor-mediated endocytosis of transferrin in
totipotent mouse teratocarcinoma cells, J. Biol. Chem. 256 (1981)
3245–3252.
[43] D.R. Richardson, E. Baker, Two saturable mechanisms of iron uptake
from transferrin in human melanoma cells: the effect of transferrin
concentration, chelators, and metabolic probes on transferrin and iron
uptake, J. Cell. Physiol. 161 (1994) 160–168.
[44] R. Gabathuler, G. Kolaitis, R.C. Brooks, Q. Chen, D.M. Karkan, G.D.
Arthur, J.P. St. Pierre, W. Jefferies, Chemotherapeutic agents conju-
gated to p97 and their methods of use in treating neurological
tumours, Int. Pub. No. 02/13843 A2, 2002.
[45] R. Gabathuler, T. Vitalis, G. Kolaitis, R.C. Brooks, D.M. Karkan,
G.D. Arthur, J.P. St. Pierre, Compositions of compounds conjugated
to p97 and their methods of use, Int. Pub. No. WO 02/13873 A2,
2002.
[46] B.C. Lim, H.J. McArdle, E.H. Morgan, Transferrin– receptor interac-
tions and iron uptake by reticulocytes of vertebrate animals—a com-
parative study, J. Comp. Physiol. 157 (1987) 363–371.
[47] E.H. Morgan, Transferrin and albumin distribution and turnover in the
rat, Am. J. Physiol. 211 (1966) 1486–1494.
[48] B.A. Cheney, K. Lothe, E.H. Morgan, S.K. Sood, C.A. Finch,
Internal iron exchange in the rat, Am. J. Physiol. 212 (1967)
376–380.
[49] E.H. Morgan, Specificity of hepatic iron uptake from plasma trans-
ferrin in the rat, Comp. Biochem. Physiol. 99A (1991) 91–95.
[50] E.M. Taylor, E.H. Morgan, Role of transferrin in iron uptake by the
brain: a comparative study, J. Comp. Physiol. 161 (1991) 521–524.
D.R. Richardson, E.H. Morgan / Biochimica et Biophysica Acta 1690 (2004) 124–133 133[51] J. Hertz, U. Hamman, S. Rogne, O. Myklebost, H. Gausepohl, H.H.
Stanley, Surface location and high affinity for calcium of a 500-kDa
liver membrane protein closely related to the LDL-receptor suggest
a physiological role as lipoprotein receptor, EMBO J. 7 (1988)
4119–4127.[52] I. Tooyama, T. Kawamata, H. Akiyama, H. Kimura, S.K. Moestrup, J.
Gliemann, A. Matsuo, P.L. McGeer, Subcellular localization of the
low density lipoprotein receptor-related protein (a2-macroglobulin
receptor) in human brain, Brain Res. 691 (1995) 235–238.
